Ovarian Cancer


Author: Clemens Tempfer Background: Primary advanced, unresectable ovarian cancer (OC) is treated with palliative systemic chemotherapy. Intraperitoneal chemotherapy may be an alternative local maintenance therapy.Case presentationA 75 year old woman with laparoscopically and histologically confirmed unresectable OC was treated with 13 cycles of intraperitoneal cisplatin 7.5 mg/m 2 and doxorubicin […]

Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian ...


Author: Marion Kiechle Background: Women with highly penetrant BRCA mutations have a 55–60% lifetime risk for breast cancer and a 16–59% lifetime risk for ovarian cancer. However, penetrance differs interindividually, indicating that environmental and behavioral factors may modify this risk. These include lifestyle factors such as physical activity status, dietary […]

Lifestyle intervention in BRCA1/2 mutation carriers: study protocol for a ...



Author: Tushar Tomar Background: In high-grade serous ovarian cancer (HGSOC), intrinsic and/or acquired resistance against platinum-containing chemotherapy is a major obstacle for successful treatment. A low frequency of somatic mutations but frequent epigenetic alterations, including DNA methylation in HGSOC tumors, presents the cancer epigenome as a relevant target for innovative […]

Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with ...


Author: Emmanouil Dermitzakis Background: Paclitaxel-based regimens are frequently associated with the development of peripheral neuropathy. The autonomous nervous system (ANS) effects, however, of this chemotherapeutic agent remain unexplored. Methods: We investigated a group of 31 female patients with ovarian cancer receiving treatment with paclitaxel and carboplatin, as well as a […]

The impact of paclitaxel and carboplatin chemotherapy on the autonomous ...



Author: Maria Vos Background: To investigate the expression of MMP-14 and CD44 as well as epithelial-to-mesenchymal transition(EMT)-like changes in ovarian cancer and to determine correlations with clinical outcome. Methods: In 97 patients with ovarian cancer, MMP-14 and CD44 expression as determined by immunohistochemistry was investigated in relation to EMT-like changes. […]

MMP-14 and CD44 in Epithelial-to-Mesenchymal Transition (EMT) in ovarian cancer




Author: Kasper Ingerslev Background: High-risk human papillomavirus (HPV) has been suspected to play a role in the carcinogenesis of epithelial ovarian cancer (EOC). However, results from previous studies are conflicting. In most of these studies, the number of tissue samples was small. The current study was therefore undertaken to examine […]

High-risk HPV is not associated with epithelial ovarian cancer in ...


Author: Atif Hashmi Background: Ovarian cancer is the most lethal gynecologic malignancy and it represents third most common malignancy in Karachi (after breast and oral cancer). Due to lack of well established cancer registry in our country, changing trends of ovarian tumors has not been determined. Therefore we aimed to […]

Clinicopathologic features of ovarian neoplasms with emphasis on borderline ovarian ...



Author: Antonella Accardo Background: Overexpression of the gastrin-releasing peptide receptor (GRP-R) has been documented in several human neoplasms such as breast, prostate, and ovarian cancer. There is growing interest in developing radiolabeled peptide-based ligands toward these receptors for the purpose of in vivo imaging and radionuclide therapy of GRP-R-overexpressing tumors. […]

Pre-clinical evaluation of eight DOTA coupled gastrin-releasing peptide receptor (GRP-R) ...


Author: Jing Yan Background: It has been proposed that cyclin G1 (CCNG1) participates in p53-dependent G 1 –S and G 2 checkpoints and might function as an oncogenic protein in the initiation and metastasis of ovarian carcinoma. MicroRNA 23b (miR-23b) is a critical regulatory factor in the progression of many […]

MiR-23b targets cyclin G1 and suppresses ovarian cancer tumorigenesis and ...



Author: Yumiko Tanaka Background: Primary epithelial ovarian carcinoma is sub-classified into serous, mucinous, endometrioid and clear cell subtypes. Neoadjuvant chemotherapy has become an alternative treatment option past several years, as serous carcinoma, the most common subtype, is known as chemotherapy-sensitive tumor. On the other hand, mucinous and clear cell carcinoma are known as chemotherapy-resistive. […]

Differentiation of epithelial ovarian cancer subtypes by use of imaging ...


Author: Wen-Ming Cao Background: Germline mutations in the BRCA1 and BRCA2 genes greatly increase a woman’s risk of developing breast and/or ovarian cancer. The prevalence and distribution of such mutations differ across races/ethnicities. Several studies have investigated Chinese women with high-risk breast cancer, but the full spectrum of the mutations […]

Novel germline mutations and unclassified variants of BRCA1 and BRCA2 ...



Author: Xiaochun Sun Background: MicroRNAs (miRNAs) are a class of small non-coding RNAs, which post-transcriptionally repress the expression of genes involved in cancer initiation and progression. Although some miRNAs that target many signaling pathways (also called universe miRNAs) are supposed to play a global role in diverse human tumors, their […]

MiR-548c impairs migration and invasion of endometrial and ovarian cancer ...


Author: Lu Deng Background: It is well-known that the treatment and monitoring methods are limited for advanced stage of endometrial carcinoma. Biological molecules with expression changes during tumor progression become potential therapeutic targets for advanced stage endometrial carcinoma. Annexin A2 (ANXA2) has been reported to be overexpressed in recurrent endometrial […]

Expression and clinical significance of annexin A2 and human epididymis ...



Author: Linlin Chang Background: Ougan (Citrus reticulata cv. Suavissima) flavedo extract (OFE) exhibited potential anti-tumor effects with unclear underlying mechanisms. This study aims to evaluate the potential anti-metastatic activities of OFE on human ovarian cancer cells, and investigate its inhibitory effect on epithelial-to-mesenchymal transition (EMT). Methods: Ougan fruits were harvested. […]

Ougan (Citrus reticulata cv. Suavissima) flavedo extract suppresses cancer motility ...


Author: Izabela Winkler Background: Regulatory T lymphocytes (Treg) are characterized by the presence of CD4+ surface antigen. Today the transcription factor FOXP3 is considered to be the most specific marker of Treg cells. The aim of the study was to estimate the percentage of Treg in peripheral blood and the […]

Regulatory T lymphocytes and transforming growth factor beta in epithelial ...




Author: Daniel J O¿Shannessy Background: Folate receptor alpha (FOLR1/FRA) is expressed in a number of epithelial cancers and in particular epithelial ovarian cancer (EOC), especially of the serous histotype. Recent studies have shown that EOC originates from the fallopian tube fimbriae rather than from epithelial cells lining the ovary. We […]

Expression of folate receptors alpha and beta in normal and ...



Author: Kimberly Glass Background: We recently identified two robust ovarian cancer subtypes, defined by the expression of genes involved in angiogenesis, with significant differences in clinical outcome. To identify potential regulatory mechanisms that distinguish the subtypes we applied PANDA, a method that uses an integrative approach to model information flow […]

A network model for angiogenesis in ovarian cancer


Author: Marianne K Kim Background: Topotecan (TPT) is a therapeutic option for women with platinum-resistant or -refractory ovarian cancer. However, the dose-limiting toxicity of TPT is myelosuppression. This led us to seek a combination treatment to augment TPT anti-cancer activity in a cancer-targeted manner. Ovarian serous cancers, a major subtype, […]

Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ...



Author: Cariad Chester Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for ovarian cancer patients are inadequate. Immunotherapy offers a novel and promising therapeutic strategy for treating ovarian tumors. Following the demonstration of the immunogenicity of ovarian tumors, multiple immunotherapeutic modalities have […]

Immunotherapeutic approaches to ovarian cancer treatment


Author: Andrew Quitadamo Background: Ovarian cancer is a deadly female reproductive cancer. Understanding the biological mechanisms underlying ovarian cancer could help lead to quicker and more accurate diagnosis and more effective treatments. Both changes in microRNA(miRNA) expression and miRNA/mRNA dysregulation have been associated with ovarian cancer. With the availability of […]

An integrated network of microRNA and gene expression in ovarian ...



Author: Karen Gambaro Background: Insulin-like growth factor binding protein 7 (IGFBP7) has been suggested to act as a tumour suppressor gene in various human cancers, yet its role in epithelial ovarian cancer (EOC) has not yet been investigated. We previously observed that IGFBP7 was one of several genes found significantly […]

Low levels of IGFBP7 expression in high-grade serous ovarian carcinoma ...


Author: Dongdong Wang Background: Cancer is well known as a leading cause of death in the world. At present, it is the very active area to search for anticancer drugs from natural products. In this study, we evaluated the antitumor property of chloroform extract (CE), n-hexane extract (HE), water extract […]

Evaluation of antitumor property of extracts and steroidal alkaloids from ...